亿帆医药股份有限公司2025年第三季度报告

Core Viewpoint - The company reported a stable growth in operating revenue and a decrease in net profit attributable to shareholders by 25.64% compared to the same period last year, primarily due to reduced income from the transfer of drug agency rights and government subsidies [3]. Financial Performance - The company did not need to restate previous accounting data, indicating stability in financial reporting [3]. - The net profit attributable to shareholders decreased by 25.64% year-on-year, attributed to a reduction in income from non-recurring gains [3]. - The company reported a total asset impairment provision of 44.31 million yuan for the first three quarters of 2025, impacting the net profit by 37.50 million yuan [15][19]. Shareholder Information - The employee stock ownership plan held 6.7754 million shares, representing 0.56% of the total share capital as of the reporting period [10]. Corporate Governance - The company held its eighth board meeting and elected new board members and senior management on September 5, 2025, completing the board renewal process [11]. Subsidiary Developments - The company’s subsidiary received multiple drug registration approvals from the National Medical Products Administration, including for oral medications and injections, indicating ongoing product development and market expansion [6][7][8].